Subtle distinct regulations of late erythroid molecular events by PI3K/AKT-mediated activation of Spi-1/PU.1 oncogene autoregulation loop

Oncogene

Volumn 29, Issue 19, 2010, Pages 2807-2816

  Breig, O ^a   Theoleyre O ^a   Douablin, A ^a   Baklouti, F ^a  

^a CENTRE DE GÉNÉTIQUE MOLÉCULAIRE ET CELLULAIRE   (France)

Author keywords

Cell differentiation; Cell signaling; Erythroleukemia; MRNA splicing

Indexed keywords

DIMETHYL SULFOXIDE; HEMOGLOBIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; SERINE; TRANSCRIPTION FACTOR PU 1;

ARTICLE; AUTOREGULATION; CELL DIFFERENTIATION; CHROMATIN IMMUNOPRECIPITATION; DOWN REGULATION; ENZYME ACTIVATION; ERYTHROID CELL; ERYTHROLEUKEMIA CELL; MUTATIONAL ANALYSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS;

FRIEND MURINE LEUKEMIA VIRUS;

EID: 77952419365     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2010.29     Document Type: Article

References (43)

1. Afrikanova I, Yeh E, Bartos D, Watowich SS, Longmore GD. (2002). Oncogene cooperativity in Friend erythroleukemia: erythropoietin receptor activation by the env gene of SFFV leads to transcriptional upregulation of PU.1, independent of SFFV proviral insertion. Oncogene 21: 1272-1284.
2. Back J, Dierich A, Bronn C, Kastner P, Chan S. (2004). PU.1 determines the self-renewal capacity of erythroid progenitor cells. Blood 103: 3615-3623.
3. Baklouti F, Huang SC, Tang TK, Delaunay J, Marchesi VT, Benz Jr EJ. (1996). Asynchronous regulation of splicing events within protein 4.1 pre-mRNA during erythroid differentiation. Blood 87: 3934-3941.
4. Bao H, Jacobs-Helber SM, Lawson AE, Penta K, Wickrema A, Sawyer ST. (1999). Protein kinase B (c-Akt), phosphatidylinositol 3-kinase, and STAT5 are activated by erythropoietin (EPO) in HCD57 erythroid cells but are constitutively active in an EPO-independent, apoptosis-resistant subclone (HCD57-SREI cells). Blood 93: 3757-3773.
5. Barnache S, Mayeux P, Payrastre B, Moreau-Gachelin F. (2001). Alterations of the phosphoinositide 3-kinase and mitogen-activated protein kinase signaling pathways in the erythropoietin-independent Spi-1/PU.1 transgenic proerythroblasts. Blood 98: 2372-2381.
6. Bavelloni A, Faenza I, Aluigi M, Ferri A, Toker A, Maraldi NM et al. (2000). Inhibition of phosphoinositide 3-kinase impairs pre-commit-ment cell cycle traverse and prevents differentiation in erythroleu-kaemia cells. Cell Death Differ 7: 112-117.
7. Blaustein M, Pelisch F, Srebrow A. (2007). Signals, pathways and splicing regulation. Int J Biochem Cell Biol 39: 2031-2048.
8. Blaustein M, Pelisch F, Tanos T, Munoz MJ, Wengier D, Quadrana L et al. (2005). Concerted regulation of nuclear and cytoplasmic activities of SR proteins by AKT. Nat Struct Mol Biol 12: 1037-1044.
9. Blaybel R, Theoleyre O, Douablin A, Baklouti F. (2008). Down-regulation of the Spi-1/PU.1 oncogene induces the expression of TRIM10/HERF1, a key factor required for terminal erythroid cell differentiation and survival. Cell Res 18: 834-845.
10. Bouscary D, Pene F, Claessens YE, Muller O, Chretien S, Fontenay-Roupie M et al. (2003). Critical role for PI 3-kinase in the control of erythropoietin-induced erythroid progenitor proliferation. Blood 101: 3436-3443.
11. Cataldi A, Di Pietro R, Centurione L, Grilli A, Cutroneo G, Miscia S. (2000). Phosphatidylinositol-3-kinase activation and atypical protein kinase C zeta phosphorylation characterize the DMSO signalling in erythroleukemia cells. Cell Signal 12: 667-672.
12. Chasis JA, Coulombel L, Conboy J, McGee S, Andrews K, Kan YW et al. (1993). Differentiation-associated switches in protein 4.1 expression. Synthesis of multiple structural isoforms during normal human erythropoiesis. J Clin Invest 91: 329-338.
13. Chen H, Ray-Gallet D, Zhang P, Hetherington CJ, Gonzalez DA, Zhang DE et al. (1995). PU.1 (Spi-1) autoregulates its expression in myeloid cells. Oncogene 11: 1549-1560.
14. Deguillien M, Huang SC, Moriniere M, Dreumont N, Benz Jr EJ, Baklouti F. (2001). Multiple cis elements regulate an alternative splicing event at 4.1R pre-mRNA during erythroid differentiation. Blood 98: 3809-3816.
15. Delgado MD, Hallier M, Meneceur P, Tavitian A, Moreau-Gachelin F. (1994). Inhibition of Friend cells proliferation by spi-1 antisense oligodeoxynucleotides. Oncogene 9: 1723-1727.
16. Delva L, Gallais I, Guillouf C, Denis N, Orvain C, Moreau-Gachelin F. (2004). Multiple functional domains of the oncoproteins Spi-1/PU.1 and TLS are involved in their opposite splicing effects in erythroleukemic cells. Oncogene 23: 4389-4399.
17. Eisenbeis CF, Singh H, Storb U. (1995). Pip, a novel IRF family member, is a lymphoid-specific, PU.1-dependent transcriptional activator. Genes Dev 9: 1377-1387.
18. Fisher RC, Slayton WB, Chien C, Guthrie SM, Bray C, Scott EW. (2004). PU.1 supports proliferation of immature erythroid progenitors. Leuk Res 28: 83-89.
19. Ghaffari S, Huang LJS, Zhang J, Lodish HF. (2003). Erythropoietin receptor signaling processes. In: Molineux G, Foote MA and Elliott SG (eds). Erythropoietins and Erythropoiesis. Birkhauser: Basel, Switzerland.
20. Jelkmann W. (2007). Erythropoietin after a century of research: younger than ever. Eur J Haematol 78: 183-205.
21. Juban G, Giraud G, Guyot B, Belin S, Diaz JJ, Starck J et al. (2009). Spi-1 and Fli-1 directly activate common target genes involved in ribosome biogenesis in Friend erythroleukemic cells. Mol Cell Biol 29: 2852-2864.
22. Maillet P, Delaunay J, Baklouti F. (1996). Chimeric probe-mediated ribonuclease protection assay for molecular diagnosis of mRNA deficiencies. Hum Mutat 7: 61-64.
23. Moreau-Gachelin F. (2008). Multi-stage Friend murine erythroleukemia: molecular insights into oncogenic cooperation. Retrovirology 5: 99.
24. Moreau-Gachelin F, Ray D, Mattei MG, Tambourin P, Tavitian A. (1989). The putative oncogene Spi-1: murine chromosomal localization and transcriptional activation in murine acute erythroleuke-mias. Oncogene 4: 1449-1456.
25. Myklebust JH, Blomhoff HK, Rusten LS, Stokke T, Smeland EB. (2002). Activation of phosphatidylinositol 3-kinase is important for erythropoietin-induced erythropoiesis from CD34(+) hematopoie-tic progenitor cells. Exp Hematol 30: 990-1000.
26. Nerlov C, Querfurth E, Kulessa H, Graf T. (2000). GATA-1 interacts with the myeloid PU.1 transcription factor and represses PU.1-dependent transcription. Blood 95: 2543-2551.
27. Nishigaki K, Hanson C, Ohashi T, Spadaccini A, Ruscetti S. (2006). Erythroblast transformation by the friend spleen focus-forming virus is associated with a block in erythropoietin-induced STAT1 phosphorylation and DNA binding and correlates with high expression of the hematopoietic phosphatase SHP-1. J Virol 80: 5678-5685.
28. Nishigaki K, Hanson C, Ohashi T, Thompson D, Muszynski K, Ruscetti S. (2000). Erythroid cells rendered erythropoietin independent by infection with Friend spleen focus-forming virus show constitutive activation of phosphatidylinositol 3-kinase and Akt kinase: involvement of insulin receptor substrate-related adapter proteins. J Virol 74: 3037-3045.
29. Okuno Y, Huang G, Rosenbauer F, Evans EK, Radomska HS, Iwasaki H et al. (2005). Potential autoregulation of transcription factor PU.1 by an upstream regulatory element. Mol Cell Biol 25: 2832-2845.
30. Patel NA, Kaneko S, Apostolatos HS, Bae SS, Watson JE, Davidowitz K et al. (2005). Molecular and genetic studies imply Akt-mediated signaling promotes protein kinase CbetaII alternative splicing via phosphorylation of serine/arginine-rich splicing factor SRp40. J Biol Chem 280: 14302-14309.
31. Paul R, Schuetze S, Kozak SL, Kozak CA, Kabat D. (1991). The Sfpi-1 proviral integration site of Friend erythroleukemia encodes the ets-related transcription factor Pu.1. J Virol 65: 464-467.
32. Pongubala JM, Van Beveren C, Nagulapalli S, Klemsz MJ, McKercher SR, Maki RA et al. (1993). Effect of PU.1 phosphor-ylation on interaction with NF-EM5 and transcriptional activation. Science 259: 1622-1625.
33. Rao G, Rekhtman N, Cheng G, Krasikov T, Skoultchi AI. (1997). Deregulated expression of the PU.1 transcription factor blocks murine erythroleukemia cell terminal differentiation. Oncogene 14: 123-131.
34. Rekhtman N, Radparvar F, Evans T, Skoultchi AI. (1999). Direct interaction of hematopoietic transcription factors PU.1 and GATA-1: functional antagonism in erythroid cells. Genes Dev 13: 1398-1411.
35. Rieske P, Pongubala JM. (2001). AKT induces transcriptional activity of PU.1 through phosphorylation-mediated modifications within its transactivation domain. J Biol Chem 276: 8460-8468.
36. Sanjuan MA, Jones DR, Izquierdo M, Merida I. (2001). Role of diacylglycerol kinase alpha in the attenuation of receptor signaling. J Cell Biol 153: 207-220.
37. Schuetze S, Paul R, Gliniak BC, Kabat D. (1992). Role of the PU.1 transcription factor in controlling differentiation of Friend erythroleukemia cells. Mol Cell Biol 12: 2967-2975.
38. Scott EW, Simon MC, Anastasi J, Singh H. (1994). Requirement of transcription factor PU.1 in the development of multiple hemato-poietic lineages. Science 265: 1573-1577.
39. Sivertsen EA, Hystad ME, Gutzkow KB, Dosen G, Smeland EB, Blomhoff HK et al. (2006). PI3K/Akt-dependent Epo-induced signalling and target genes in human early erythroid progenitor cells. Br J Haematol 135: 117-128.
40. Tarn WY. (2007). Cellular signals modulate alternative splicing. J Biomed Sci 14: 517-522.
41. Theoleyre O, Deguillien M, Moriniere M, Starck J, Moreau-Gachelin F, Morle F et al. (2004). Spi-1/PU.1 but not Fli-1 inhibits erythroid-specific alternative splicing of 4.1R pre-mRNA in murine erythro-leukemia cells. Oncogene 23: 920-927.
42. Yamada T, Kondoh N, Matsumoto M, Yoshida M, Maekawa A, Oikawa T. (1997). Overexpression of PU.1 induces growth and differentiation inhibition and apoptotic cell death in murine erythroleukemia cells. Blood 89: 1383-1393.
43. Zhang P, Behre G, Pan J, Iwama A, Wara-Aswapati N, Radomska HS et al. (1999). Negative cross-talk between hematopoietic regulators: GATA proteins repress PU.1. Proc Natl Acad Sci USA 96: 8705-8710.